Evidence map›Paper›PMID 34424927›Full record

ArticlePloS one2021

Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain.

Shaojing Ye, Fei Ma, Dlovan F D Mahmood, Katherine L Meyer-Siegler, Raymond E Menard, David E Hunt, Lin Leng, Richard Bucala, Pedro L Vera

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Large-Scale Plasma Proteomics to Profile Pathways and Prognosis of Chronic Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shaojing YeResearch & Development, Lexington VA Health Care System, Lexington, KY, United States of America.
Fei MaResearch & Development, Lexington VA Health Care System, Lexington, KY, United States of America.
Dlovan F D MahmoodResearch & Development, Lexington VA Health Care System, Lexington, KY, United States of America.
Katherine L Meyer-SieglerDepartment of Natural Sciences, St Petersburg College, St Petersburg, FL, United States of America.
Raymond E MenardDepartment of Natural Sciences, St Petersburg College, St Petersburg, FL, United States of America.
David E HuntResearch & Development, Lexington VA Health Care System, Lexington, KY, United States of America.
Lin LengDepartment of Internal Medicine, Yale University, New Haven, CT, United States of America.
Richard BucalaDepartment of Internal Medicine, Yale University, New Haven, CT, United States of America.
Pedro L VeraResearch & Development, Lexington VA Health Care System, Lexington, KY, United States of America.ORCID 0000-0003-2785-7218
Lexington VA Health Care System · USSt. Petersburg College · USYale University · USUniversity of Kentucky · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Macrophage Migration Inhibitory Factor mediates bladder painR01DK121695 · NIDDK · LEXINGTON BIOMEDICAL RESEARCH INSTITUTE · PI VERA, PEDRO L · 2019 to 2022
$959k
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS R01 DK121695
6 · The paper itself

Abstract

backgroundActivation of intravesical protease activated receptor 4 (PAR4) leads to release of urothelial macrophage migration inhibitory factor (MIF). MIF then binds to urothelial MIF receptors to release urothelial high mobility group box-1 (HMGB1) and elicit bladder hyperalgesia. Since MIF binds to multiple receptors, we investigated the contribution of individual urothelial MIF receptors to PAR4-induced HMGB1 release in vivo and in vitro and bladder pain in vivo. METHODOLOGY/PRINCIPAL

findingsWe tested the effect of intravesical pre-treatment with individual MIF or MIF receptor (CD74, CXCR4, CXCR2) antagonists on PAR4-induced HMGB1 release in vivo (female C57/BL6 mice) and in vitro (primary human urothelial cells) and on PAR4-induced bladder hyperalgesia in vivo (mice). In mice, PAR4 induced HMGB1 release and bladder hyperalgesia through activation of intravesical MIF receptors, CD74 and CXCR4. CXCR2 was not involved in these effects. In primary urothelial cells, PAR4-induced HMGB1 release through activation of CD74 receptors. Micturition parameters in mice were not changed by any of the treatments. CONCLUSIONS/SIGNIFICANCE: Urothelial MIF receptors CD74 and CXCR4 mediate bladder pain through release of urothelial HMGB1. This mechanism may set up persistent pain loops in the bladder and warrants further investigation. Urothelial CD74 and CXCR4 may provide novel targets for interrupting bladder pain.

Indexed as

AdultAnimalsAntigens, Differentiation, B-LymphocyteFemaleHistocompatibility Antigens Class IIHMGB1 ProteinHumansHyperalgesiaMacrophage Migration-Inhibitory FactorsMaleMiceMice, Inbred C57BLReceptors, CXCR4Receptors, ImmunologicReceptors, ThrombinUrinary BladderAntigens, Differentiation, B-LymphocyteCXCR4 protein, mouseHistocompatibility Antigens Class IIHMGB1 Proteininvariant chainmacrophage migration inhibitory factor receptorMacrophage Migration-Inhibitory Factorsprotease-activated receptor 4Receptors, CXCR4Receptors, ImmunologicReceptors, Thrombin

Identifiers

PMID34424927
PMCPMC8382170
OpenAlexW3195326853

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.